<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941796</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ROMA-106</org_study_id>
    <nct_id>NCT02941796</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics and Safety After Administration of HCP1105 Alone and Co-administration of HGP0918 and HGP0816 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the pharmacokinetic properties and safety after administration of HCP1105 and
      co-administration of HGP0918, HGP0816 in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetic properties and safety after
      administration of HCP1105 and co-administration of HGP0918, HGP0816 in healthy male
      volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>baseline-corrected Cmax of DHA total lipid &amp; EPA total lipid</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>baseline-corrected AUCt of DHA total lipid &amp; EPA total lipid</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Rosuvastatin</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of Rosuvastatin</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of DHA total lipid &amp; EPA total lipid</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt of DHA total lipid &amp; EPA total lipid</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of DHA total lipid &amp; EPA total lipid</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of DHA total lipid &amp; EPA total lipid</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>baseline-corrected partial AUC12/24/48 of DHA total lipid &amp; EPA total lipid</measure>
    <time_frame>-20, -16, -12, 0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72hr (Total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC∞ of Rosuvastatin</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Rosuvastatin</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of Rosuvastatin</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Rosuvastatin</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vdz/F of Rosuvastatin</measure>
    <time_frame>0(predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hr (Total 13)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T → R
T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R → T
T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1105</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP0918</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP0816</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have ability to comprehend the objectives, contents of study and property
             of study drug before participating in trial and have willingness to sign of informed
             consent in writing

          -  Healthy male volunteers, aged 19 to 55 years.

          -  The result of Body Mass Index(BMI) is not less than 18.5 kg/m2 , no more than 27.0
             kg/m2

        Exclusion Criteria:

          -  •Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in digestive system, neuropsychiatric system, endocrine system,
             liver, cardiovascular system

               -  Someone has a declined liver function and Liver enzyme (AST, ALT or total
                  bilirubin) level exceeds more than one and a half times normal upper range

               -  Somenone has a declined kidney function and his eGFR &lt; 60mL/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

